STOCKS TELEGRAPH

Tag: OCUP stock

  • Why Is Ocuphire (OCUP) Stock So Hot In Premarket?

    Why Is Ocuphire (OCUP) Stock So Hot In Premarket?

    At last check, shares of Ocuphire Pharma Inc. (OCUP) were up 32.84% to trade at $6.31 in pre-market trading. On Wednesday, Ocuphire stock fell -2.06% to close at $4.75. Volume for OCUP stock stayed at 0.39 million shares, meaning it was a lower daily volume than its average of 0.42 million shares in the past 50 days. OCUP’s market capitalization stands at 57.67 million dollars and it have 10.92 million shares outstanding. OCUP stock is gaining traction after encouraging results of a clinical trial.

    Why did that trial take place?

    Ocuphire develops and commercializes therapies for the treatment of several eye conditions through its clinical-stage ophthalmic biopharmaceutical platform. In the course of pursuing its strategy, OCUP will continue to explore opportunities to acquire additional ophthalmic assets and to search for strategic partners to assist with drug development, regulatory preparation, and commercialization efforts in key global markets.

    In its VEGA-1 Phase 2 clinical trial, Ocuphire announced today that the primary and many secondary endpoints for its clinical study of Nyxol combined with low dose pilocarpine (LDP) in presbyopic subjects have been met.

    Key highlights:

    • In photopic binocular near vision, 61% of Nyxol + LDP subjects improved by 15 letters or more at 1 hour compared with 28% of placebo subjects.
    • Phase 3 co-primary endpoint of OCUP demonstrated 15 letters (3 lines) of improvement in near vision while only losing less than 5 letters in distance vision.
    • A rapid onset of efficacy was noted by the OCUP within 30 minutes.
    • Through at least 6 hours, OCUP observed a sustained improvement in near vision.
    • OCUP reported near vision efficacy in both monocular and binocular view.
    • By observing both its efficacy in light as well as dark iris colors, OCUP has identified that it is effective.
    • OCUP trial unveiled that Nyxol + LDP was generally well tolerated.
    • According to OCUP, there were no serious adverse events (AE) while most of AEs were mild in nature.
    • The OCUP trial did not send serious adverse events, nor did there appear to be any headaches or brow aches.

    Ocuphire (OCUP) plans to move on to Phase 3 as a result of these results. Nyxol + LDP has the potential for differentiation and to be a best-in-class product for treating presbyopia, OCUP believes, given its rapid onset and sustained duration of efficacy, favorable safety profile, and potential tunability of treatment.

    Trial summary:

    The Based on these results, Nyxol works by contracting the iris dilator muscle, which results in a smaller pupil size and beneficial effects on presbyopia. In the recent clinical studies by Ocuphire (OCUP), Nyxol plus LDP combination is demonstrated to have a rapid onset of action and long-lasting effect while maintaining good distance vision at night and day. The OCUP found all treatments to be well tolerated and safe. OCUP views Nyxol + LDP as one of the most promising treatment options for presbyopia.

  • Ocuphire Pharma Inc. (OCUP) stock soared in the recent trading session: here’s why

    OcuphirePharma Inc. (OCUP) stock recently traded at $6.43 which is a 0.78% upward movement. The OCUP stock previously closed at $6.38.

    The pattern of positive movement in recent trading session has been correlated with the news released on an analyst giving the OCUP stock a “Buy” after initiating coverage on it.

    OccuphirePharma’s current pipeline projects

    OccuphirePharma (OCUP) is a clinical-stage biopharmaceutical company which focuses on the specialization of developing and commercializing ophthalmic treatments for several eye disorders. OCUP is also publicly traded company. Its current pipeline consists of two-small molecule product that is acting as candidates targeting the eye indications.

    • Nyxol Eye Drops is the lead product candidate which consists of 0.75% phentolamine ophthalmic solutions. Designed to reduce pupil size to tackle dim light and night vision disturbance along with several other indications.
    • APX3330 is an oral tablet designed to inhibit the retinal inflammation pathway and choroidal vascular diseases.

    Nyxol has passed the phase 3 trial in RM and is now in phase 3 trial for NVD’s clinical development. APX3330 is now in the phase 2 trial for clinical development of Diabetic Retinopathy (DR) and Diabetic Macular edema (DME).

    Analyst rating for OCUP stock

    Investors believe to be hyped about the recent developments in the Nyxol 0.75% which can target a large and significant market of unmet ophthalmic needs. This operational progress is also one of the reasons that Alliance Global Partners has initiated coverage on OcuphirePharma with Buy Rating. There are 2 more ratings on the firm lately. JoneTrading initiated coverage on OCUP stock in the previous month and has given a Buy rating as well. Cantor Fitzgerald has maintained its coverage and gives an overweight rating since March 2021.

    OCUP has announced equity and options rewards for its employees

    On 1st April 2021, OcuphirePharma (OCUP) had announced the equity award approval under Ocuphire’s inducement plan as a material inducement to Erik Sims. This approval was done through the compensation committee of the Board of Directors in OCUP. The equity award was given to Erik Sims in regard to his role within the company as Controller of the Company. This award was made effective since the announcement date and under accordance with Nasdaq listing rule 5635(c)(4).

    Occuphire has also given Options awards for the employees who just started working with the company. This option provided the opportunity to purchase an aggregate of 38,000 shares of the OCUP’s common stock. The option will have a 10 year term and a 4 year period vest. The vesting percentage every year will be divided to 25% each 12 months.

    Future potential of OCUP stock

    Overall all eyes of investors and stakeholders are on the operational progress; specifically for the clinical trial phase 3 of Nylox 0.75 to succeed. The commercial roll-out of Nylox would enter a million dollar market due to unmet needs. The analyst ratings give a boost to the stock’s performance and will attract further investors to invest in OCUP stock.